RxDoctor Payments DataLook up a doctor →

Edgardo Faylona, MD

Hematology & Oncology · Las Vegas, NVNPI 1083611362

Payments from drug & device makers

$53,128in general payments, 2019–2025

Across 459 payments — averaging $115.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Gilead$4K
  • Exelixis Inc.$4K
  • Pfizer$3K
  • Taiho Oncology, Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)51$18,147
Gilead(2 entities)26$4,349
Exelixis Inc.16$4,266
Pfizer33$3,476
Taiho Oncology, Inc.3$2,960
E.r. Squibb & Sons, L.L.C.19$2,737
Sobi, Inc10$2,511
Beigene USA, Inc.1$1,925
Daiichi Sankyo Inc.10$1,204
Bristol Myers Squibb20$1,060
Bayer6$977
Incyte Corporation13$912
Novartis35$825
Johnson & Johnson(2 entities)15$731
Amgen36$690
Lilly USA, LLC18$661
Regeneron Healthcare Solutions, Inc.12$602
Genentech USA, Inc.22$590
UCB, Inc.10$494
Astellas Pharma US Inc8$409
AVEO Pharmaceuticals, Inc.4$352
Stemline Therapeutics Inc.5$272
Sanofi6$263
Eisai Inc.5$258
Acadia Pharmaceuticals Inc1$233
Seagen Inc.7$204
EMD Serono, Inc.4$199
Takeda Pharmaceuticals U.S.A., Inc.4$169
Medtronic1$158
AbbVie2$140
Argenx US, Inc.1$128
Novocure Inc.1$120
Merck8$118
Comsort, Inc1$100
GSK4$98
Biogen1$96
Pharmacyclics LLC, An Abbvie Company5$89
Dova Pharmaceuticals3$63
Boehringer Ingelheim3$60
Octapharma USA, Inc.3$56
Mylan Institutional Inc.2$30
Sun Pharmaceutical Industries Inc.1$28
Foundation Medicine, Inc.2$27
Clovis Oncology, Inc.2$27
Teva Pharmaceuticals USA, Inc.2$26
Viiv Healthcare Company1$25
Ipsen Biopharmaceuticals, Inc1$25
Epizyme, Inc.1$22
Servier Pharmaceuticals LLC1$21
Heron Therapeutics, Inc.1$20
Myovant Sciences Inc.1$18
Global Blood Therapeutics, Inc.1$18
Jazz Pharmaceuticals Inc.1$17
Novo Nordisk1$17
Shire North American Group Inc1$15
Bio Products Laboratory USA, Inc.1$15
Dendreon Pharmaceuticals LLC1$15
Array Biopharma Inc1$13
Tesaro, Inc.1$13
Karyopharm Therapeutics Inc.1$12

How this compares

$53,128 in reported general payments places this provider in the 55th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$658,129
Medicare patients
218
Services billed
27,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →